Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Esophageal Achalasia01:27

Esophageal Achalasia

37
Esophageal achalasia is a chronic neurogenic disorder characterized by impaired relaxation of the lower esophageal sphincter (LES) and absent or ineffective peristalsis in the distal esophagus. This leads to a functional obstruction without a physical blockage, despite significant disruption of esophageal motility.EtiologyAchalasia is caused by degeneration of the myenteric (Auerbach's) plexus, specifically the loss of inhibitory ganglion cells that produce vasoactive intestinal peptide...
37
Barrett Esophagus-II: Clinical Manifestations and Management01:21

Barrett Esophagus-II: Clinical Manifestations and Management

1.8K
Individuals with Barrett's esophagus are often asymptomatic, but they may experience symptoms commonly associated with GERD, such as heartburn and acid regurgitation. Additional symptoms can include difficulty swallowing, chest pain, unintentional weight loss, blood in the stool (which may appear black, tarry, or bloody), and episodes of vomiting.
To diagnose Barrett's esophagus, healthcare providers often recommend an endoscopy for those showing symptoms of acid reflux. The procedure...
1.8K
Gastroesophageal Reflux Disease01:25

Gastroesophageal Reflux Disease

39
Gastroesophageal reflux disease (GERD) is the backward flow of stomach contents (acid, pepsin, or bile) into the esophagus, causing mucosal inflammation known as esophagitis. It results from failure of antireflux mechanisms, mainly the lower esophageal sphincter (LES), influenced by mechanical and physiological factors.Etiology and Risk FactorsGERD develops when LES function is weakened or when intra-abdominal pressure increases. Risk factors include aging, obesity, and sliding hiatal hernia,...
39
Barrett Esophagus-I: Introduction01:21

Barrett Esophagus-I: Introduction

1.5K
Barrett's esophagus is a medical condition where the esophageal mucosa is significantly damaged by stomach acid or other digestive fluids, often due to long-term exposure associated with gastroesophageal reflux disease (GERD). In GERD, a weakened or abnormally relaxed lower esophageal sphincter allows stomach acid to flow persistently into the esophagus.
This constant acid exposure transforms the esophagus's pink mucosal lining (stratified squamous epithelium) into a type of lining more...
1.5K
Esophageal Varices-II: Clinical Features and Management01:28

Esophageal Varices-II: Clinical Features and Management

880
Esophageal varices often manifest as gastrointestinal bleeding episodes, presenting symptoms like hematemesis (vomiting of blood), hematochezia (passing fresh blood via the rectum), and melena (black, tarry stools). Other signs can include weight loss, anorexia, abdominal discomfort, jaundice, pruritus, altered mental status, and muscle cramps.
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol...
880
Peptic Ulcer Disease III: Clinical Manifestations and Diagnostic Studies01:28

Peptic Ulcer Disease III: Clinical Manifestations and Diagnostic Studies

999
Peptic ulcer disease (PUD) presents with diverse symptoms depending on the location and severity of the ulcer. Clinical manifestations of peptic ulcer include dull pain and a burning sensation in the mid-epigastric region.
Few clinical manifestations differentiate gastric ulcers from duodenal ulcers. Distinctions in the location, timing, and pain relief are crucial for healthcare providers in differentiating between gastric and duodenal ulcers during clinical assessments.
999

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Postoperative Delirium: A Survey of Perceptions Among Surgical Providers.

Delirium (Bielefeld, Germany)·2026
Same author

Increased risk of stroke after heart transplant in patients bridged with prolonged Impella 5.5 support.

The International journal of artificial organs·2026
Same author

Early prediction of postoperative delirium in major surgery patients using multimodal preoperative EHR and medical notes: a retrospective cohort study in the Indiana network for patient care.

BMJ public health·2026
Same author

Machine learning and artificial intelligence for delirium prediction with Electronic Health Records (EHR): a scoping review.

BMC medical informatics and decision making·2026
Same author

Impella 5.5 Versus Intra-Aortic Balloon Pump for Bridging Heart Transplant Patients: A Contemporary Analysis of the United Network for Organ Sharing Database.

ASAIO journal (American Society for Artificial Internal Organs : 1992)·2025
Same author

Impella 5.5 versus intra-aortic balloon pump for bridging dual organ heart-kidney transplants: Analysis of the UNOS database.

The International journal of artificial organs·2025

Related Experiment Video

Updated: Apr 27, 2026

Development of Compendium for Esophageal Squamous Cell Carcinoma
03:36

Development of Compendium for Esophageal Squamous Cell Carcinoma

Published on: April 12, 2024

970

Glycomic expression in esophageal disease.

Sanjay Mohanty1, Athanasios Tsiouris2, Zane Hammoud3

  • 1Henry Ford Hospital, 2799 W. Grand Blvd., Detroit, MI 48202, USA. smohant1@hfhs.org.

Metabolites
|June 25, 2014
PubMed
Summary
This summary is machine-generated.

Aberrant protein glycosylation is linked to cancer. Glycoproteomic analysis reveals distinct glycan profiles in esophageal cancer progression, offering potential biomarkers for early detection and management.

More Related Videos

Diagnosis of Neoplasia in Barrett’s Esophagus using Vital-dye Enhanced Fluorescence Imaging
06:55

Diagnosis of Neoplasia in Barrett’s Esophagus using Vital-dye Enhanced Fluorescence Imaging

Published on: May 11, 2014

10.5K
Simultaneous Laryngopharyngeal and Conventional Esophageal pH Monitoring
06:46

Simultaneous Laryngopharyngeal and Conventional Esophageal pH Monitoring

Published on: December 14, 2020

2.8K

Related Experiment Videos

Last Updated: Apr 27, 2026

Development of Compendium for Esophageal Squamous Cell Carcinoma
03:36

Development of Compendium for Esophageal Squamous Cell Carcinoma

Published on: April 12, 2024

970
Diagnosis of Neoplasia in Barrett’s Esophagus using Vital-dye Enhanced Fluorescence Imaging
06:55

Diagnosis of Neoplasia in Barrett’s Esophagus using Vital-dye Enhanced Fluorescence Imaging

Published on: May 11, 2014

10.5K
Simultaneous Laryngopharyngeal and Conventional Esophageal pH Monitoring
06:46

Simultaneous Laryngopharyngeal and Conventional Esophageal pH Monitoring

Published on: December 14, 2020

2.8K

Area of Science:

  • Biochemistry
  • Oncology
  • Proteomics

Background:

  • Glycosylation, a common protein modification, is crucial for cellular function.
  • Aberrant glycosylation patterns are increasingly recognized as hallmarks of malignant transformation.
  • Esophageal adenocarcinoma (EAC) progresses through distinct stages from metaplasia to neoplasia.

Purpose of the Study:

  • To review current glycomic and glycoproteomic literature on esophageal cancer.
  • To highlight the potential of glycan profiles as biomarkers for EAC progression.
  • To emphasize the utility of glycoproteomics in understanding EAC pathogenesis.

Main Methods:

  • Literature review of glycomic and glycoproteomic studies.
  • Analysis of glycan profiles associated with different stages of esophageal cancer.
  • Comparison of glycan alterations in EAC versus other cancers.

Main Results:

  • Glycoproteomic studies have identified specific glycan profiles linked to high-grade dysplasia and malignancy in EAC.
  • Distinct glycan differences are observed across EAC progression stages (metaplasia, dysplasia, neoplasia).
  • Glycan profile changes in EAC are more pronounced than in other cancer types.

Conclusions:

  • Glycan biomarkers hold significant promise for predicting EAC progression and guiding clinical management.
  • Glycoproteomics provides a powerful approach to unraveling EAC biology and identifying diagnostic/prognostic markers.
  • Understanding glycosylation changes is critical for advancing EAC research and patient outcomes.